Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients

Clinical Immunology

Volumn 106, Issue 1, 2003, Pages 10-15

  Engleman, Edgar G ^a   Fong, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN;

B CELL LYMPHOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CARCINOMA; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; HUMAN; IMMUNITY; IMMUNIZATION; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VACCINATION;

EID: 0037288731     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(02)00016-5     Document Type: Review

References (28)

1. Lynch R.G., Rohrer J.W., Odermatt B., Gebel H.M., Autry J.R., Hoover R.G. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol. Rev. 48:1979;45-80.
2. Hsu F.J., Kwak L., Campbell M., Liles T., Czerwinski D., Hart S., Syrengelas A., Miller R., Levy R. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann. N.Y. Acad. Sci. 690:1993;385-387.
3. Maloney D.G., Kaminski M.D., Burowski D., Haimovich J., Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13 characterization and use as probes for the biology of the tumor in vivo and in vitro . Hybridoma. 4:1985;191-209.
4. Carroll W.L., Lowder J.N., Streifer R., Warnke R., Levy S., Levy R. Idiotype variant cell populations in patients with B cell lymphoma. J. Exp. Med. 164:1986;1566-1580.
5. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52-58.
6. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., Taidi B., Rajapaksa R., Caspar C.B., Okada C.Y., van Beckhoven A., Liles T.M., Engleman E.G., Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma clinical and immune responses in 35 patients . Blood. 99:2002;1517-1526.
7. Thompson J.A., Grunert F., Zimmerman W. Carcinoembryonic antigen gene family molecular biology and clinical perspectives . J. Clin. Lab. Anal. 5:1991;344-366.
8. Sikorska H., Shuster J., Gold P. Clinical application of carcinoembryonic antigen. Cancer Detect. Prev. 12:1988;321-355.
9. Steward A.M., Nixon D., Zamcheck N., Aisenberg A. Carcinoembryonic antigen in breast cancer patients serum levels and disease progress . Cancer. 33:1974;1246-1252.
10. Vincent R.G., Chu T.M. Carcinoembryonic antigen in patients with carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 66:1978;320-328.
11. Shively J.E., Beatty J.D. CEA-related antigens Molecular biology and clinical significance . Crit. Rev. Oncol. Hematol. 2:1985;355-399.
12. Hostetter R.B., Augustus L.B., Mankarious R., Chi K., Fan D., Toth C., Thomas P., Jessup J.M. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J. Nat. Cancer Inst. 82:1990;380-385.
13. Hammarstrom S. The carcinoembryonic antigen (CEA) family structures, suggested functions and expression in normal and malignant tissues . Semin. Cancer Biol. 9:1999;67-81.
14. Mitchell E.P. Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin. Oncol. 25:1998;12-20.
15. Kantor J., Irvine K., Abrams S., Kaufman H., Di Pietro J., Schlom J. Anti-tumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84:1992;1084-1091.
16. Kass E., Schlom J., Thompson J., Guadagni F., Graziano P., Greiner J.W. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59:1999;676-683.
17. Zaremba S., Barzaga E., Zhu M., Soares N., Tsang K.Y., Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57:1997;4570-4657.
18. Salazar E., Zaremba S., Arlen P.M., Tsang K.Y., Schlom J. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. J. Cancer. 85:2000;829-838.
19. Lyman S.D., Jacobsen S.E. c-kit ligand and Flt3 ligand stem/progenitor cell factors with overlapping yet distinct activities . Blood. 91:1998;1101-1134.
20. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice multiple dendritic cell subpopulations identified . J. Exp. Med. 184:1996;1953-1962.
21. Altman J.D., Moss P.A., Goulder P.J., Barousk D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
22. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., Johnson D., Swetter S., Thompson J., Greenberg P.D., Roederer M., Davis M.M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
23. Fong L., Brockstedt D., Benike C., Wu L., Engleman E.G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166:2001;4254-4259.
24. Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., Engleman E.G. Dendritic cell based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167:2001;7150-7156.
25. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
26. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N., Pineiro L., Steinman R., Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:2001;6451-6458.
27. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., Bender A., Feurstein B., Fritsch P.O., Romani N., Schuler G. Rapid Induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:2002;1279-1288.
28. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.